Coty Reports Q2 Results Amid Weak Consumer Beauty Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 15 2026
0mins
Source: NASDAQ.COM
Coty Inc's shares fell by 21.59% as the company hit a 52-week low amid disappointing earnings results.
Coty reported Q2 results showing a net revenue of $1.678 billion, a slight increase year-over-year, but an adjusted net income loss of $126.9 million raised concerns. The company has withdrawn its FY26 guidance for EBITDA and free cash flow, anticipating a mid-single-digit percentage decline in Q3 revenues primarily due to weakening trends in Consumer Beauty sales. This has led to a significant drop in investor confidence, contributing to the stock's decline.
The implications of these results indicate that Coty is facing substantial challenges in the competitive beauty market, and the strategic framework 'Coty. Curated.' may need to be more aggressively implemented to regain market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COTY
Wall Street analysts forecast COTY stock price to rise
12 Analyst Rating
1 Buy
9 Hold
2 Sell
Hold
Current: 1.900
Low
2.50
Averages
4.30
High
10.00
Current: 1.900
Low
2.50
Averages
4.30
High
10.00
About COTY
Coty Inc. is a beauty company with a portfolio of brands across fragrance, color cosmetics, and skin and body care. The Company has a diverse portfolio of brands, which includes both owned and licensed. Its brand portfolio is classified into two segments: Consumer beauty and Prestige. The consumer beauty brands include Adidas, Beckham, Bozzano, Bourjois, Bruno Banani, CoverGirl, Jovan, Mexx, LeGer by Lena Gercke, Monange, Nautica, Paixao, Rimmel, Risque, Sally Hansen, and Vera Wang. Its prestige brands include Burberry, Calvin Klein, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Kylie Cosmetics by Kylie Jenner, Lancaster, Marc Jacobs, Miu Miu, Orveda, and Tiffany & Co. Its mass beauty brands are primarily sold through hypermarkets, supermarkets, drug stores and pharmacies, mid-tier department stores, traditional food and drug retailers, and dedicated e-commerce retailers. It markets, sells and distributes its products in over 120 countries and territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BellRing Brands Dropped from S&P Index Amid Market Struggles
- Significant Stock Decline: BellRing Brands' shares plummeted nearly 10% during Monday's trading session, closing at $7.90, indicating investor concerns regarding its removal from the S&P MidCap 400 index and reflecting worries about the company's future performance.
- Index Adjustment Impact: S&P Global announced that BellRing will be replaced in the S&P MidCap 400 index by new entrants like Roku, with the adjustment aimed at ensuring the index better represents market capitalization ranges; while such changes typically have little impact on fundamentals, they highlight BellRing's recent market struggles.
- Reduced Market Capitalization: BellRing's market cap has shrunk to $1 billion, underscoring its challenges in the competitive protein products market, which may erode investor confidence in its growth potential and lead to further stock price volatility.
- Investor Guidance: Despite the potential for short-term stock price fluctuations due to index exclusion, analysts advise investors to focus on BellRing's performance, strategy, and financial position rather than making long-term investment decisions solely based on index membership.
See More
BellRing Brands to Exit S&P 400 MidCap Index
- Index Component Change: BellRing Brands (NYSE: BRBR) is set to be removed from the S&P 400 MidCap Index, and while this change is expected to have little impact on its fundamentals, the market reacted negatively, causing shares to drop nearly 10% during Monday's trading session.
- Market Reaction Analysis: The quarterly rebalancing announced by S&P Global after market close on Friday replaced BellRing's stock with new entrants like Roku and Coeur Mining, raising investor concerns about the company's shrinking market cap, which contributed to the significant decline in share price.
- Investor Recommendations: Analysts emphasize that investors should not base their buy or sell decisions solely on whether a company is part of a well-known index, but rather focus on BellRing's performance, strategy, and financial position to make more informed investment choices.
- Market Performance Comparison: Although BellRing Brands did not make it onto the Motley Fool Stock Advisor's list of the 10 best stocks, the average return of this list stands at 941%, significantly outperforming the S&P 500's 206%, indicating a market preference for high-quality stocks.
See More
Coty Inc. Shareholder Class Action Notice
- Shareholder Lawsuit Notice: The Gross Law Firm issues a notice to Coty Inc. shareholders, encouraging those who purchased shares between November 5, 2025, and February 4, 2026, to contact the firm for potential lead plaintiff appointment to partake in recovery.
- Performance Warning: Coty revealed in its Q2 FY 2026 financial results that its Consumer Beauty segment underperformed, leading to the withdrawal of its EBITDA guidance, reflecting slowing growth and compressed margins due to increased marketing investments.
- Significant Stock Decline: Coty's stock price plummeted from $3.43 per share on February 4, 2026, to $2.66 per share by February 6, 2026, marking a 22% decline, indicating strong market concerns regarding the company's performance and outlook.
- Management Change Impact: Alongside the disappointing results, Coty announced a CEO transition, highlighting issues of “operational discipline” within the company, which may further undermine investor confidence amid ongoing market challenges.
See More
Coty Shareholder Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, to apply as lead plaintiffs by May 22, 2026, or risk losing representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected shareholders to join the litigation.
- Lawsuit Background: The lawsuit alleges that Coty made false and misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses when the truth emerged, highlighting the company's vulnerabilities in market competition.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases, prompting investors to carefully select experienced legal counsel.
See More
Coty Faces Expanded Securities Class Action Lawsuit
- Expanded Lawsuit Timeline: Hagens Berman has filed a new securities class action against Coty in the Southern District of New York, extending the recovery period to May 7, 2025, through February 4, 2026, thereby providing a broader opportunity for all investors who purchased Coty stock during this timeframe to seek compensation.
- Allegations of Concealed Performance: The lawsuit alleges that Coty failed to disclose significant underperformance in the consumer beauty market, aggressive profit margin compression due to unsustainable marketing investments, and a sharp deceleration in prestige fragrance growth during the expanded period, misleading investors about the company's true operational health.
- Stock Price Collapse Impact: Following the February 4, 2026 financial results announcement revealing over a 70% year-over-year drop in operating income for the consumer beauty segment and an 18% decline in prestige fragrance income, Coty's stock plummeted approximately 22% from $3.43 to $2.66 per share, erasing hundreds of millions in shareholder value.
- Investor Action Call: Hagens Berman urges Coty investors who suffered significant losses during the expanded period to submit their claims promptly and encourages witnesses with relevant information to contact the firm to assist in the investigation and potentially benefit from the SEC Whistleblower program.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
BellRing Brands Dropped from S&P Index Amid Market Struggles
- Significant Stock Decline: BellRing Brands' shares plummeted nearly 10% during Monday's trading session, closing at $7.90, indicating investor concerns regarding its removal from the S&P MidCap 400 index and reflecting worries about the company's future performance.
- Index Adjustment Impact: S&P Global announced that BellRing will be replaced in the S&P MidCap 400 index by new entrants like Roku, with the adjustment aimed at ensuring the index better represents market capitalization ranges; while such changes typically have little impact on fundamentals, they highlight BellRing's recent market struggles.
- Reduced Market Capitalization: BellRing's market cap has shrunk to $1 billion, underscoring its challenges in the competitive protein products market, which may erode investor confidence in its growth potential and lead to further stock price volatility.
- Investor Guidance: Despite the potential for short-term stock price fluctuations due to index exclusion, analysts advise investors to focus on BellRing's performance, strategy, and financial position rather than making long-term investment decisions solely based on index membership.
See More
BellRing Brands to Exit S&P 400 MidCap Index
- Index Component Change: BellRing Brands (NYSE: BRBR) is set to be removed from the S&P 400 MidCap Index, and while this change is expected to have little impact on its fundamentals, the market reacted negatively, causing shares to drop nearly 10% during Monday's trading session.
- Market Reaction Analysis: The quarterly rebalancing announced by S&P Global after market close on Friday replaced BellRing's stock with new entrants like Roku and Coeur Mining, raising investor concerns about the company's shrinking market cap, which contributed to the significant decline in share price.
- Investor Recommendations: Analysts emphasize that investors should not base their buy or sell decisions solely on whether a company is part of a well-known index, but rather focus on BellRing's performance, strategy, and financial position to make more informed investment choices.
- Market Performance Comparison: Although BellRing Brands did not make it onto the Motley Fool Stock Advisor's list of the 10 best stocks, the average return of this list stands at 941%, significantly outperforming the S&P 500's 206%, indicating a market preference for high-quality stocks.
See More
Coty Inc. Shareholder Class Action Notice
- Shareholder Lawsuit Notice: The Gross Law Firm issues a notice to Coty Inc. shareholders, encouraging those who purchased shares between November 5, 2025, and February 4, 2026, to contact the firm for potential lead plaintiff appointment to partake in recovery.
- Performance Warning: Coty revealed in its Q2 FY 2026 financial results that its Consumer Beauty segment underperformed, leading to the withdrawal of its EBITDA guidance, reflecting slowing growth and compressed margins due to increased marketing investments.
- Significant Stock Decline: Coty's stock price plummeted from $3.43 per share on February 4, 2026, to $2.66 per share by February 6, 2026, marking a 22% decline, indicating strong market concerns regarding the company's performance and outlook.
- Management Change Impact: Alongside the disappointing results, Coty announced a CEO transition, highlighting issues of “operational discipline” within the company, which may further undermine investor confidence amid ongoing market challenges.
See More
Coty Shareholder Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Coty Inc. (NYSE: COTY) common stock between November 5, 2025, and February 4, 2026, to apply as lead plaintiffs by May 22, 2026, or risk losing representation in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected shareholders to join the litigation.
- Lawsuit Background: The lawsuit alleges that Coty made false and misleading statements during the class period, concealing the true state of its slowing growth in the beauty market, which resulted in investor losses when the truth emerged, highlighting the company's vulnerabilities in market competition.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases, prompting investors to carefully select experienced legal counsel.
See More
Coty Faces Expanded Securities Class Action Lawsuit
- Expanded Lawsuit Timeline: Hagens Berman has filed a new securities class action against Coty in the Southern District of New York, extending the recovery period to May 7, 2025, through February 4, 2026, thereby providing a broader opportunity for all investors who purchased Coty stock during this timeframe to seek compensation.
- Allegations of Concealed Performance: The lawsuit alleges that Coty failed to disclose significant underperformance in the consumer beauty market, aggressive profit margin compression due to unsustainable marketing investments, and a sharp deceleration in prestige fragrance growth during the expanded period, misleading investors about the company's true operational health.
- Stock Price Collapse Impact: Following the February 4, 2026 financial results announcement revealing over a 70% year-over-year drop in operating income for the consumer beauty segment and an 18% decline in prestige fragrance income, Coty's stock plummeted approximately 22% from $3.43 to $2.66 per share, erasing hundreds of millions in shareholder value.
- Investor Action Call: Hagens Berman urges Coty investors who suffered significant losses during the expanded period to submit their claims promptly and encourages witnesses with relevant information to contact the firm to assist in the investigation and potentially benefit from the SEC Whistleblower program.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
